Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome.
Batra G, Ghukasyan Lakic T, Lindbäck J, Held C, White HD, Stewart RAH, Koenig W, Cannon CP, Budaj A, Hagström E, Siegbahn A, Wallentin L; STABILITY Investigators.
Batra G, et al.
JAMA Cardiol. 2021 Dec 1;6(12):1440-1445. doi: 10.1001/jamacardio.2021.3079.
JAMA Cardiol. 2021.
PMID: 34431970
Free PMC article.
Clinical Trial.
Using predefined strata, elevated IL-6 level ( 2.0 vs <2.0 ng/L) was associated with increased risk of MACE at normal kidney function (2.9% vs 1.9% events/y [hazard ratio, 1.35; 95% CI, 1.02-1.78]), mild CKD (3.3% vs 1.9% [hazard ratio, 1.57; 95% CI, 1.35-1.83]), and mo …
Using predefined strata, elevated IL-6 level ( 2.0 vs <2.0 ng/L) was associated with increased risk of MACE at normal kidney function (2. …